Stock Price Quote

SUVEN LIFE SCIENCES LTD.

NSE : SUVENBSE : 530239ISIN CODE : INE495B01038Industry : Pharmaceuticals & DrugsHouse : Private
BSE106.40-0.45 (-0.42 %)
PREV CLOSE ( ) 106.85
OPEN PRICE ( ) 106.15
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 20440
TODAY'S LOW / HIGH ( )103.50 107.00
52 WK LOW / HIGH ( )45.01 128.79
NSE105.40-1.1 (-1.03 %)
PREV CLOSE( ) 106.50
OPEN PRICE ( ) 108.00
BID PRICE (QTY) 105.40 (1000)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 117093
TODAY'S LOW / HIGH( ) 102.90 108.00
52 WK LOW / HIGH ( )45 129
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 09-03 1989
Management Info
Venkateswarlu Jasti - Chairman - Managing Director
Registered Office

Address 8-2-334, S D E Serene Chambers,6th Floor, Road No 5, Avenue 7,Banjara Hills,
Hyderabad,
Telangana-500034

Phone 040- 23541142 /3315 / 23543311

Email info@suven.com

Website www.suven.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, MCX

NEWS

29Jan Suven Pharmaceuticals informs about bo
Suven Pharmaceuticals has informed that a Meeting of the Board of Direct..
12Jan Clarification sought from Suven Life
The Exchange has sought clarification from Suven Life Sciences Ltd on Ja..
23Nov Suven Pharmaceuticals informs about BRSR
Suven Pharmaceuticals has informed that the present report has been comp..
26Sep Suven Pharmaceuticals informs about di
Suven Pharmaceuticals has informed that the Company has received an inti..
16Sep Suven Life Sciences informs about loss
Suven Life Sciences has informed regarding loss of share certificate und..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit-47.69-201.27
Gross Profit -47.69 -201.27
Operating Profit -31.33-192.95
Net Sales 24.51135.39

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

NGL Fine-Chem (BSE)
peergroup  2174.05 (2.26%)
M.Cap ( in Cr)1343.13
Astrazeneca Pharma I (BSE)
peergroup  5495.90 (0.60%)
M.Cap ( in Cr)13739.75
RPG Life Sciences (BSE)
peergroup  1660.40 (1.91%)
M.Cap ( in Cr)2746.14
Windlas Biotech (BSE)
peergroup  546.65 (5.60%)
M.Cap ( in Cr)1136.95
Dishman Carbogen Amc (BSE)
peergroup  238.65 (10.10%)
M.Cap ( in Cr)3741.63

Shareholding Pattern

PROMOTERS 69.57%
NON-INSTITUTION 29.89%
MUTUAL FUNDS/UTI 0.01%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Suven Life Sciences Ltd.

Suven Life Sciences Ltd. was incorporated in the year 1989. Its today's share price is 106.4. Its current market capitalisation stands at Rs 2320.3 Cr. In the latest quarter, company has reported Gross Sales of Rs. 135.39 Cr and Total Income of Rs.219.88 Cr. The company's management includes Sudha Rani Jasti, Shrenik Soni, JAS Padmaja, Santanu Mukherjee, M Gopalakrishna, Seyed E Hasnain, Venkateswarlu Jasti.

It is listed on the BSE with a BSE Code of 530239 , NSE with an NSE Symbol of SUVEN and ISIN of INE495B01038. It's Registered office is at 8-2-334, S D E Serene Chambers,6th Floor, Road No 5, Avenue 7,Banjara HillsHyderabad-500034, Telangana. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Karvy & Co, Tukaram & Co, Tukaram & Co LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.